Something meaningful is shifting in how India’s most vulnerable patients access the medicines they need. For years, the super speciality pharmacy space operated on phone calls, guesswork, and geography, a system that worked well for those who knew how to move through it and fell short for everyone else. Today, artificial intelligence is rewriting those rules, and the change is arriving faster than most anticipated.

Smarter Search, Faster Discovery

For years, access to super speciality medicines in India has been shaped by information asymmetry. Patients navigating serious conditions often face multiple challenges at once: identifying the right medicine, understanding its cost, confirming availability, managing complex treatment protocols, and discovering financial assistance programs that could significantly reduce their burden.

Patient Support Programs (PSPs), manufacturer-funded initiatives that can help cover treatment costs, provide nurse counselling, and guide patients through therapy, have long remained underutilized because many patients simply do not know they exist. Artificial intelligence is beginning to change that reality. Rather than addressing individual pain points in isolation, AI is helping connect the entire patient journey, from discovery and pricing to availability, adherence, and education.

AI-powered search and recommendation systems can now help patients identify relevant medicines, surface eligible support programs, provide multilingual guidance, and connect them with trusted pharmacy networks. For patients managing life-altering conditions, faster access to accurate information can be as important as access to the medicine itself.

Machine Learning and the Opacity Problem in Drug Pricing

A 2024 Public Library of Science (PLOS) Digital Health study found that an estimated 98% of cancer patients in India cannot afford immuno-oncology therapies when recommended by their physicians. That single figure contains everything wrong with how drug pricing works in this country. Patients are routinely handed a price at the counter with no context, no comparison, and no recourse. Drug pricing in India, particularly for patented super-speciality therapies, has long operated as a black box.

An AWS case study on Amazon Pharmacy found that simply showing patients their prescription costs upfront, before dispensing, materially improved adherence without changing what they actually paid. The lesson for the Indian context is pointed. Machine-learning-powered tools that surface price benchmarks across suppliers, flag patient assistance programme eligibility, and identify biosimilar or generic alternatives are no longer a product feature. They are a mechanism for keeping patients in treatment.

In practice, AI can help make pricing more transparent by identifying lower-cost therapeutic alternatives where clinically appropriate, highlighting biosimilars and generics, and automatically matching eligible patients with assistance programs. What was once a fragmented and opaque process can increasingly become a personalized and data-driven experience, enabling patients to make informed treatment decisions before cost becomes a reason to discontinue care.

Predictive Analytics and the Availability Gap

Traditional pharmacy has a structural blind spot: low-volume, high-criticality medicines. The economics of retail stocking rarely justify holding inventory for drugs with limited turnover, and most pharmacies simply do not. The consequence plays out in patients’ lives every day. A 2024 industry report found that over half of medicines required at the Delhi State Cancer Institute were unavailable at any given time.

Predictive analytics lets platforms order the right molecules weeks before a patient needs them, instead of days after they’ve run out. By training models on historical prescription data, oncologist ordering patterns, seasonal disease incidence, and regional demographics, specialty pharmacy platforms can anticipate demand for these low-volume molecules weeks ahead of time. This shifts procurement from reactive scrambling to deliberate planning, a change that has real consequences for patients in the middle of a treatment cycle.

A 2024 IMARC Group analysis of India’s pharmaceutical sector noted that AI-driven forecasting is now generating supply visibility that traditional inventory management simply cannot match.

Patient-Centric AI: From Dosage Guidance to Adherence

Beyond logistics, some of AI’s most consequential work in speciality pharmacy happens after the medicine reaches the patient. Complex regimens, including oral chemotherapy, biologics requiring precise timing and refrigeration, and drugs with narrow therapeutic windows, demand a level of ongoing patient education that point-of-sale interactions rarely deliver. This plays out directly in the industry: patients who receive structured digital follow-up, dosage reminders, side-effect check-ins, refill prompts, stay on therapy significantly longer than those who do not.

Digital monitoring tools are particularly effective at detecting self-medication errors before they become clinical incidents, catching the kind of quiet non-compliance that a quarterly clinic visit never would. In a country as linguistically and geographically diverse as India, AI-powered counselling flows, multilingual reminder systems, and intelligent follow-up tools represent a scalable alternative to the specialist pharmacist hours that most patients never get access to.

Regulation, Ethics, and the Road Ahead

What this moment calls for is not just better technology but a more honest reckoning with what access to medicine actually requires. AI is proving that the barriers patients face, finding the right drug, understanding what it costs, trusting it will be available, and staying on therapy are not separate problems but parts of the same broken chain.

Also Read: How AI – led fraud detection is reshaping health insurance claims management in India.

At the same time, responsible adoption matters. AI is not a substitute for clinical judgment, nor can it solve every structural challenge in healthcare delivery. Questions around data privacy, algorithmic bias, transparency, and equitable access must remain central to how these systems are designed and deployed. The objective should be to augment pharmacists, physicians, and patient-support teams, not replace them.

Addressed together, intelligently and responsibly, they become solvable. That means platforms must be as rigorous about who their systems serve as they are about how well those systems perform, ensuring that the benefits of AI reach patients in tier-two cities and rural districts just as readily as those in urban centres. It also means the industry, regulators, and technology providers need to move in step, because no single stakeholder can close this gap alone. AI is now giving us the tools to reach the patients who have waited the longest, and who can wait no longer.

Views expressed by: Devashish Singh, Co-Founder & CEO, MrMed 

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

Disclaimer: The views and opinions expressed in this article are solely those of the author and do not necessarily reflect the official policy or views of any organisation. The content is intended for informational and educational purposes only and should not be construed as medical advice.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!